3,3′-Diindolylmethane inhibits the invasion and metastasis of nasopharyngeal carcinoma cells in vitro and in vivo by regulation of epithelial mesenchymal transition

Experimental and Therapeutic Medicine

Volumn 7, Issue 6, 2014, Pages 1635-1638

  Wu, Tingting ^a   Chen, Chen ^a   Li, Fen ^a   Chen, Zhe ^a   Xu, Yong ^a   Xiao, Botui ^a   Tao, Zezhang ^a  

^a RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

3,3 diindolylmethane; Epithelial mesenchymal transition; Invasion; Metastasis; Nasopharyngeal carcinoma cell

Indexed keywords

3, 3' DIINDOLYLMETHANE; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; TRANSCRIPTION FACTOR SLUG; TRANSCRIPTION FACTOR SNAIL; UNCLASSIFIED DRUG; UVOMORULIN; VIMENTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER TRANSPLANTATION; CELL MIGRATION ASSAY; CONTROLLED STUDY; EPITHELIAL MESENCHYMAL TRANSITION; FEMALE; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; METASTASIS INHIBITION; MOUSE; NASOPHARYNX CARCINOMA; NONHUMAN; PROTEIN EXPRESSION; TUMOR INVASION; TUMOR XENOGRAFT; WESTERN BLOTTING;

EID: 84898450647     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2014.1649     Document Type: Article

References (38)

1. Lo KW, To KF and Huang DP: Focus on nasopharyngeal carcinoma. Cancer Cell 5: 423-428, 2004.
2. Lo KW, Chung GT and To KF: Deciphering the molecular genetic basis of NPC through molecular, cytogenetic, and epigenetic approaches. Semin Cancer Biol 22: 79-86, 2012.
3. Jemal A, Bray F, Center M. M, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin 61: 69-90, 2011.
4. Lee AW, Sze WM, Au JS, et al: Treatment results for nasopharyngeal carcinoma in the modern era: the Hong Kong experience. Int J Radiat Oncol Biol Phys 61: 1107-1116, 2005.
5. He JR, Shen GP, Ren ZF, et al: Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma. Head Neck 34: 1769-1776, 2012.
6. Huang PY, Wang CT, Cao KJ, et al: Pretreatment body mass index as an independent prognostic factor in patients with locoregionally advanced nasopharyngeal carcinoma treated with chemoradiotherapy: findings from a randomised trial. Eur J Cancer 49: 1923-1931, 2013.
7. Lee AW, Poon YF, Foo W, et al: Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: overall survival and patterns of failure. Int J Radiat Oncol Biol Phys 23: 261-270, 1992.
8. Tofilon PJ and Camphausen K: Molecular targets for tumor radiosensitization. Chem Rev 109: 2974-2988, 2009.
9. Ho FC, Tham IW, Earnest A, Lee KM and Lu JJ: Patterns of regional lymph node metastasis of nasopharyngeal carcinoma: a meta-analysis of clinical evidence. BMC Cancer 12: 98, 2012.
10. Kim SJ, Lee JS and Kim SM: 3,3′-Diindolylmethane suppresses growth of human esophageal squamous cancer cells by G1 cell cycle arrest. Oncol Rep 27: 1669-1673, 2012.
11. Shorey LE, Hagman AM, Williams DE, Ho E, Dashwood RH and Benninghoff AD: 3,3′-Diindolylmethane induces G1 arrest and apoptosis in human acute T-cell lymphoblastic leukemia cells. PLoS One 7: e34975, 2012.
12. Yin XF, Chen J, Mao W, Wang YH and Chen MH: A selective aryl hydrocarbon receptor modulator 3,3′-Diindolylmethane inhibits gastric cancer cell growth. J Exp Clin Cancer Res 31: 46, 2012.
13. Zhu J, Li Y, Guan C and Chen Z: Anti-proliferative and pro-apoptotic effects of 3,3′-diindolylmethane in human cervical cancer cells. Oncol Rep 28: 1063-1068, 2012.
14. Chen C, Chen SM, Xu B, et al: In vivo and in vitro study on the role of 3,3′-diindolylmethane in treatment and prevention of nasopharyngeal carcinoma. Carcinogenesis 34: 1815-1821, 2013.
15. Pan Y and Claret FX: Targeting Jab1/CSN5 in nasopharyngeal carcinoma. Cancer Lett 326: 155-160, 2012.
16. Cheng SH, Jian JJ, Tsai SY, et al: Long-term survival of nasopharyngeal carcinoma following concomitant radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 48: 1323-1330, 2000.
17. Lee AW, Tung SY, Ngan RK, et al: Factors contributing to the efficacy of concurrent-adjuvant chemotherapy for locoregionally advanced nasopharyngeal carcinoma: combined analyses of NPC-9901 and NPC-9902 Trials. Eur J Cancer 47: 656-666, 2011.
18. Xiao WW, Huang SM, Han F, et al: Local control, survival, and late toxicities of locally advanced nasopharyngeal carcinoma treated by simultaneous modulated accelerated radiotherapy combined with cisplatin concurrent chemotherapy: long-term results of a phase 2 study. Cancer 117: 1874-1883, 2011.
19. Pan ZQ, He XY, Guo XM, et al: A phase III study of late course accelerated hyperfractionated radiotherapy versus conventionally fractionated radiotherapy in patients with nasopharyngeal carcinoma. Am J Clin Oncol 35: 600-605, 2012.
20. Peng G, Wang T, Yang KY, et al: A prospective, randomized study comparing outcomes and toxicities of intensity-modulated radiotherapy vs. conventional two-dimensional radiotherapy for the treatment of nasopharyngeal carcinoma. Radiother Oncol 104: 286-293, 2012.
21. Cao CN, Luo JW, Gao L, et al: Clinical outcomes and patterns of failure after intensity-modulated radiotherapy for T4 nasopharyngeal carcinoma. Oral Oncol 49: 175-181, 2013.
22. Chen Y, Sun Y, Liang SB, et al: Progress report of a randomized trial comparing long-term survival and late toxicity of concurrent chemoradiotherapy with adjuvant chemotherapy versus radiotherapy alone in patients with stage III to IVB nasopharyngeal carcinoma from endemic regions of China. Cancer 119: 2230-2238, 2013.
23. Zhang W, Dou H, Lam C, et al: Concurrent chemoradiotherapy with or without adjuvant chemotherapy in intermediate and locoregionally advanced nasopharyngeal carcinoma. Tumour Biol 34: 1729-1736, 2013.
24. Huber MA, Kraut N and Beug H: Molecular requirements for epithelial-mesenchymal transition during tumor progression. Curr Opin Cell Biol 17: 548-558, 2005.
25. Lee JM, Dedhar S, Kalluri R and Thompson EW: The epithelial-mesenchymal transition: new insights in signaling, development, and disease. J Cell Biol 172: 973-981, 2006.
26. Yang J and Weinberg RA: Epithelial-mesenchymal transition: at the crossroads of development and tumor metastasis. Dev Cell 14: 818-829, 2008.
27. Tsai JH, Donaher JL, Murphy DA, Chau S and Yang J: Spatiotemporal regulation of epithelial-mesenchymal transition is essential for squamous cell carcinoma metastasis. Cancer Cell 22: 725-736, 2012.
28. Grünert S, Jechlinger M and Beug H: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis. Nat Rev Mol Cell Biol 4: 657-665, 2003.
29. Kalluri R and Weinberg RA: The basics of epithelial-mesenchymal transition. J Clin Invest 119: 1420-1428, 2009.
30. Onder TT, Gupta PB, Mani SA, Yang J, Lander ES and Weinberg RA: Loss of E-cadherin promotes metastasis via multiple downstream transcriptional pathways. Cancer Res 68: 3645-3654, 2008.
31. De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer 13: 97-110, 2013.
32. Scanlon CS, Van Tubergen EA, Inglehart RC and D'Silva NJ: Biomarkers of epithelial-mesenchymal transition in squamous cell carcinoma. J Dent Res 92: 114-121, 2013.
33. Shirkoohi R: Epithelial mesenchymal transition from a natural gestational orchestration to a bizarre cancer disturbance. Cancer Sci 104: 28-35, 2013.
34. Wong TS, Chan WS, Li CH, et al: Curcumin alters the migratory phenotype of nasopharyngeal carcinoma cells through up-regulation of E-cadherin. Anticancer Res 30: 2851-2856, 2010.
35. Xu L, Jiang Y, Zheng J, et al: Aberrant expression of β-catenin and E-cadherin is correlated with poor prognosis of nasopharyngeal cancer. Hum Pathol 44: 1357-1364, 2013.
36. Nieto MA: The snail superfamily of zinc-finger transcription factors. Nat Rev Mol Cell Biol 3: 155-166, 2002.
37. Cano A, Pérez-Moreno MA, Rodrigo I, et al: The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression. Nat Cell Biol 2: 76-83, 2000.
38. Luo W, Fang W, Li S and Yao K: Aberrant expression of nuclear vimentin and related epithelial-mesenchymal transition markers in nasopharyngeal carcinoma. Int J Cancer 131: 1863-1873, 2012.